IPCA Laboratories

IPCA Laboratories Buyback Yield

Buyback Yield of IPCA Laboratories (IPCALAB.NS) as of Nov 17, 2026.

Buyback Yield

0.00

Last updated:

Buyback Yield of IPCA Laboratories is 2026 0.00 . Buyback Yield of IPCA Laboratories was 2025 0.00 . It decreases by % lower compared to the previous year.

The IPCA Laboratories Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2019
0.01 INR
Jan 1, 2020
0.03 INR
Jan 1, 2021
0.09 INR
Jan 1, 2022
0.00 INR
Jan 1, 2023
0.00 INR
Jan 1, 2024
0.00 INR
Jan 1, 2025
0.00 INR
Jan 1, 2026
0.00 INR
The IPCA Laboratories Buyback Yield history
YEARBuyback YieldYoY
0.00—
0.00—
0.00—
0.00—
0.00-100.00%
0.09 %+199.92%
0.03 %+161.27%
0.01 %—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

On Eulerpool you can find the complete historical development of Buyback Yield IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IPCA Laboratories

All Key Metrics — IPCA Laboratories